These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9790165)

  • 21. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of recent clinical studies with olanzapine.
    Tollefson GD; Kuntz AJ
    Br J Psychiatry Suppl; 1999; (37):30-5. PubMed ID: 10211139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The promise of new drugs for schizophrenia treatment.
    Tamminga CA
    Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
    Madhusoodanan S; Suresh P; Brenner R; Pillai R
    Ann Clin Psychiatry; 1999 Sep; 11(3):113-8. PubMed ID: 10482120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Return of menstruation after switching from risperidone to olanzapine.
    Gazzola LR; Opler LA
    J Clin Psychopharmacol; 1998 Dec; 18(6):486-7. PubMed ID: 9864085
    [No Abstract]   [Full Text] [Related]  

  • 26. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 27. Risperidone side effects.
    Conley RR
    J Clin Psychiatry; 2000; 61 Suppl 8():20-3; discussion 24-5. PubMed ID: 10811239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
    Ho BC; Miller D; Nopoulos P; Andreasen NC
    J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of olanzapine for elderly patients with psychotic disorders: a review.
    Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O
    Ann Clin Psychiatry; 2001 Dec; 13(4):201-13. PubMed ID: 11958362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some aspects of psychodynamic response to novel atypical antipsychotics.
    Murawiec S; Taflińska D; Tafliński T
    Harv Rev Psychiatry; 1999; 7(4):241-2. PubMed ID: 10579106
    [No Abstract]   [Full Text] [Related]  

  • 34. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Service use and costs of treating schizophrenia with atypical antipsychotics.
    Lewis M; McCrone P; Frangou S
    J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 39. Olanzapine: a new atypical antipsychotic.
    Littrell K; Peabody CD; Littrell SH
    J Psychosoc Nurs Ment Health Serv; 1996 Aug; 34(8):41-6. PubMed ID: 8856604
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.